Sign in
Join
Help
VetSurgeon.
org
Home
News
Discussions
Jobs
Films
Films
All films
Veterinary Controversies
Veterinary Costs
Talking Points
Product Briefings
Cardiology
Dentistry
Dermatology
Diagnostic Imaging
Equine
Exotics
Farm Animal
Neurology
Ophthalmology
Orthopaedics
Pathology/Cytology
Soft Tissue Surgery
Menu
NEWS
NEWS
Email updates
Email updates
LATEST JOBS
Royal Tunbridge Wells
Small Animal Vet
Dundee City
Small Animal Vet
Berkhamsted
Small Animal Vet
Yate
Small Animal Vet
View all veterinary jobs
Options
Subscribe by email
More
Cancel
All Headlines >>
RSPCA slams new Pfizer drug for dogs
Arlo Guthrie
VetSurgeon News
/cfs-filesystemfile/__key/communityserver-components-sitefiles/graphics-logos/vetsurgeon_2D00_news.gif?_=636335966444922000
Comments
0
12 Oct 2007 4:39 PM
The
RSPCA
has come out against
Slentrol
, Pfizer’s new dieting drug for dogs, in the
Daily Mail
this week.
The charity’s senior scientist, Dr Jane Cooper told the Mail that the drug could cause side-effects such as vomiting and diarrhoea, and that the tests needed to bring the drug to market had led to the suffering of many dogs, cats and other animals, some of which were subsequently put down.
Given that just about every drug has potential side-effects and all are required by law to undergo testing, it seems the only purpose of these highly emotive and calculated comments is to inflict the maximum damage to Pfizer.
In an ideal world, all dog owners would feed their pets correctly, and take them for a brisk walk every day. But we don’t live in an ideal world, and the reality is that whatever the RSPCA has to say on the matter, there will remain a significant number of pet owners that only ever get off their backsides to go and get themselves a beer, and the dog a treat.
Is it right or responsible that the RSPCA should, through this kind of statement, deny these animals some relief from their owners? Is it responsible for the RSPCA to pan a drug the moment it comes to market, or would it have been a more pragmatic move for the charity to work behind the scenes to try and ensure that it is used appropriately?
0 Comments
RELATED NEWS
VMD approves three-month injection for canine osteoarthritis pain
Accord launches lower-cost dexmedetomidine option for UK practices
The Pet Vet and Optivet partnership brings specialist ophthalmology referrals to London
New diagnostic tool aims to show where practice owners are carrying too much pressure
Topics
RSPCA
Product News
Internal medicine
DISCUSSION
What do YOU think about this news? Log in or register to comment.
Log in
or
create an account
to join the discussion.
Claim CPD
Add the time spent on this item to my VetSurgeon.org Personal Development Record
Time Spent (minutes)
What I learned?
How will I put what I learned into practice?
Submit